Total Payments
$217,539
2024 Payments
$2,548
Companies
21
Transactions
183
Medicare Patients
8,229
Medicare Billing
$1.5M
Payment Breakdown by Category
Research$168,163 (77.3%)
Consulting$23,463 (10.8%)
Travel$12,832 (5.9%)
Food & Beverage$7,941 (3.7%)
Other$5,064 (2.3%)
Education$75.30 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $168,163 | 22 | 77.3% |
| Consulting Fee | $23,463 | 5 | 10.8% |
| Travel and Lodging | $12,832 | 11 | 5.9% |
| Food and Beverage | $7,941 | 140 | 3.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,000 | 2 | 2.3% |
| Education | $75.30 | 2 | 0.0% |
| Long term medical supply or device loan | $64.25 | 1 | 0.0% |
Payments by Type
Research
$168,163
22 transactions
General
$49,376
161 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $165,100 | 6 | $0 (2019) |
| Allergan, Inc. | $27,131 | 36 | $0 (2021) |
| Ocular Therapeutix, Inc. | $15,824 | 16 | $0 (2022) |
| Alcon Vision LLC | $2,278 | 42 | $0 (2024) |
| ABBVIE INC. | $2,271 | 24 | $0 (2024) |
| Alcon Laboratories Inc | $2,104 | 22 | $0 (2018) |
| Carl Zeiss Meditec, Inc. | $1,174 | 9 | $0 (2021) |
| Carl Zeiss Meditec USA, Inc. | $510.16 | 6 | $0 (2023) |
| HOYA Medical Singapore PTE LTD | $218.16 | 1 | $0 (2018) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $169.74 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,548 | 20 | ABBVIE INC. ($2,026) |
| 2023 | $1,081 | 20 | Alcon Vision LLC ($585.66) |
| 2022 | $949.52 | 18 | Carl Zeiss Meditec USA, Inc. ($445.91) |
| 2021 | $895.81 | 15 | Alcon Vision LLC ($539.73) |
| 2020 | $376.55 | 13 | Alcon Vision LLC ($140.10) |
| 2019 | $34,171 | 33 | Bausch Health US, LLC ($22,100) |
| 2018 | $167,926 | 40 | Bausch Health US, LLC ($143,000) |
| 2017 | $9,591 | 24 | Ocular Therapeutix, Inc. ($6,428) |
All Payment Transactions
183 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $29.06 | General |
| Category: Ophthalmology | ||||||
| 10/31/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $28.05 | General |
| Category: EYE CARE | ||||||
| 10/22/2024 | Alcon Vision LLC | LenSx (Device) | Food and Beverage | In-kind items and services | $25.59 | General |
| Category: Ophthalmology | ||||||
| 09/30/2024 | Alcon Vision LLC | LenSx (Device) | Food and Beverage | In-kind items and services | $125.51 | General |
| Category: Ophthalmology | ||||||
| 09/22/2024 | ABBVIE INC. | — | — | In-kind items and services | $862.96 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/21/2024 | ABBVIE INC. | — | — | In-kind items and services | $348.25 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/21/2024 | ABBVIE INC. | — | — | In-kind items and services | $69.99 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/21/2024 | ABBVIE INC. | — | — | In-kind items and services | $59.99 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/21/2024 | ABBVIE INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/21/2024 | ABBVIE INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/20/2024 | ABBVIE INC. | — | — | In-kind items and services | $348.25 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/20/2024 | ABBVIE INC. | — | — | In-kind items and services | $153.77 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 08/22/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: EYE CARE | ||||||
| 07/30/2024 | Alcon Vision LLC | Clareon (Device) | Food and Beverage | In-kind items and services | $25.72 | General |
| Category: Ophthalmology | ||||||
| 05/02/2024 | Alcon Vision LLC | Clareon (Device) | Food and Beverage | In-kind items and services | $149.42 | General |
| Category: Ophthalmology | ||||||
| 04/16/2024 | RxSight Inc | RXSIGHT CONTACT LENS (Device), RXSIGHT INJECTOR CARTRIDGE, RXSIGHT INJECTOR HANDPIECE | Food and Beverage | In-kind items and services | $143.45 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/19/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $25.01 | General |
| Category: EYE CARE | ||||||
| 03/18/2024 | Rayner Intraocular Lenses Limited | Omidria (Drug), RayOne EMV, RayOne Spheric | Food and Beverage | Cash or cash equivalent | $22.74 | General |
| Category: Ophthalmology | ||||||
| 02/06/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $31.67 | General |
| Category: EYE CARE | ||||||
| 01/09/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $33.48 | General |
| Category: EYE CARE | ||||||
| 12/13/2023 | Alcon Vision LLC | Clareon (Device) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Ophthalmology | ||||||
| 12/12/2023 | AbbVie Inc. | LUMIGAN (Drug), ALPHAGAN P | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: EYE CARE | ||||||
| 11/07/2023 | AbbVie Inc. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: EYE CARE | ||||||
| 11/03/2023 | Alcon Vision LLC | — | Food and Beverage | In-kind items and services | $180.26 | General |
| Category: Ophthalmology | ||||||
| 11/01/2023 | AbbVie Inc. | ALPHAGAN P (Drug), LUMIGAN | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: EYE CARE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Masked, Active-Controlled, Parallel Group, Multi-Center Bioequivalence Study of the Generic Brinzolamide 1 Ophthalmic Suspension Compared to Reference Listed Drug Azopt Brinzolamide Ophthalmic Suspension 1 in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension. | Bausch Health US, LLC | $143,000 | 4 |
| A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PARALLEL GROUP, MULTI-CENTER BIOEQUIVELENCE STUDY OF THE GENERIC BRINZOLAMIDE 1 OPHTHALMIC SUSPENSION COMPARED TO BRANDED BRINZOLAMIDE 1 OPHTHALMIC SUSPENSION AZOPT IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION | Bausch Health US, LLC | $22,100 | 2 |
| A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ABBVIE INC. | $1,893 | 8 |
| A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment | Allergan Inc. | $951.97 | 7 |
| MOON Study | HOYA Medical Singapore PTE LTD | $218.16 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,784 | 2,079 | $1.5M | $352,568 |
| 2022 | 12 | 1,908 | 2,259 | $2.0M | $349,302 |
| 2021 | 11 | 2,135 | 2,807 | $2.0M | $377,935 |
| 2020 | 11 | 2,402 | 2,965 | $2.1M | $424,833 |
Total Patients
8,229
Total Services
10,110
Medicare Billing
$1.5M
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 66984 | Removal of cataract with insertion of prosthetic lens | Facility | 2023 | 324 | 584 | $977,800 | $232,872 | 23.8% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2023 | 111 | 111 | $166,558 | $38,064 | 22.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 216 | 216 | $106,935 | $24,123 | 22.6% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2023 | 335 | 337 | $48,503 | $12,223 | 25.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 111 | 114 | $43,460 | $10,458 | 24.1% |
| 92025 | Ct scan of cornea | Office | 2023 | 352 | 375 | $19,327 | $9,592 | 49.6% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 99 | 101 | $38,852 | $7,688 | 19.8% |
| 66982 | Complex removal of cataract with insertion of prosthetic lens | Facility | 2023 | 11 | 12 | $26,977 | $6,283 | 23.3% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 68 | 68 | $31,124 | $5,504 | 17.7% |
| 92134 | Imaging of retina | Office | 2023 | 95 | 97 | $11,844 | $3,003 | 25.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 19 | $5,139 | $1,182 | 23.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 22 | 22 | $3,744 | $976.08 | 26.1% |
| 92133 | Imaging of optic nerve | Office | 2023 | 22 | 23 | $2,581 | $600.12 | 23.3% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Facility | 2022 | 314 | 560 | $1.5M | $221,325 | 15.2% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2022 | 93 | 93 | $150,836 | $31,645 | 21.0% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 292 | 292 | $136,979 | $29,350 | 21.4% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 294 | 304 | $120,384 | $26,412 | 21.9% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2022 | 336 | 379 | $56,416 | $13,009 | 23.1% |
| 92025 | Ct scan of cornea | Office | 2022 | 350 | 376 | $42,576 | $9,229 | 21.7% |
| 66982 | Complex removal of cataract with insertion of prosthetic lens | Facility | 2022 | 14 | 16 | $43,200 | $8,659 | 20.0% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 91 | 101 | $28,291 | $6,056 | 21.4% |
| 92134 | Imaging of retina | Office | 2022 | 61 | 68 | $7,995 | $1,914 | 23.9% |
| 92133 | Imaging of optic nerve | Office | 2022 | 34 | 40 | $3,916 | $863.74 | 22.1% |
| 92083 | Exam of visual field with extended testing | Office | 2022 | 17 | 18 | $3,576 | $731.81 | 20.5% |
| 76514 | Ultrasound scan of cornea to determine thickness | Office | 2022 | 12 | 12 | $432.00 | $106.51 | 24.7% |
About Dr. Thomas Walters, MD
Dr. Thomas Walters, MD is a Ophthalmology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1609852664.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Walters, MD has received a total of $217,539 in payments from pharmaceutical and medical device companies, with $2,548 received in 2024. These payments were reported across 183 transactions from 21 companies. The most common payment nature is "" ($168,163).
As a Medicare-enrolled provider, Walters has provided services to 8,229 Medicare beneficiaries, totaling 10,110 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Austin, TX
- Active Since 12/21/2005
- Last Updated 01/03/2024
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1609852664
Products in Payments
- BRINZOLAMIDE (Drug) $143,000
- AZOPT (Drug) $22,100
- ReSure Sealant (Device) $15,736
- LUMIGAN (Drug) $9,281
- AcrySof (Device) $1,262
- Centurion (Device) $708.57
- Clareon (Device) $695.92
- IOLMaster 500 (Device) $460.34
- ARTEVO 800 (Device) $340.09
- AcrySof IQ PanOptix (Device) $254.95
- ORA (Device) $243.99
- VisuMax (Device) $235.95
- LenSx (Device) $231.70
- ARGOS (Device) $226.88
- FORUM (Device) $209.58
- ZEISS CATARACT SUITE MARKERLESS (Device) $198.40
- RXSIGHT CONTACT LENS (Device) $143.45
- AcrySof IQ VIVITY IOL (Device) $138.99
- VUITY (Drug) $133.24
- ILUX (Device) $132.94
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Austin
Vikram Durairaj, Md, MD
Ophthalmology — Payments: $516,103
Ophthalmology $516,103
Dr. Sheila Barbarino, M.d, M.D
Ophthalmology — Payments: $236,894
Ophthalmology $236,894
Chirag Jhaveri, M.d, M.D
Ophthalmology — Payments: $211,408
Ophthalmology $211,408
Dr. Steven Dell, M.d, M.D
Ophthalmology — Payments: $177,840
Ophthalmology $177,840
Dr. Aaron Roller, M.d, M.D
Ophthalmology — Payments: $154,063
Ophthalmology $154,063
Robert Wong, Md, MD
Ophthalmology — Payments: $118,721
Ophthalmology $118,721